Figure 1From: Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study Serum trough levels measured at 2 consecutive visits in RA patients with stable DAS28 and infliximab dosing. Back to article page